



USPTO Form 1449 Patent and Trademark Office				U.S. Department of Commerce		Attorney Docket No. 11111/2003G		Serial No. 10/667,193	
INFORMATION DISCLOSURE STATEMENT						Applicant(s): Segal, et al.			
						Filing Date: September 19, 2003		Group: Not Yet Assigned	
U.S. PATENT DOCUMENTS									
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)		
FOREIGN PATENT DOCUMENTS									
Examiner Initial		Document No.	Publication Date	Country	Class	Subclass	Translation		
							YES	NO	
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)									
de	1.	Faulkner, L. et al., (2001), "IL-2 linked to a peptide from influenza hemagglutinin enhances T cell activation by affecting the antigen-presentation function of bone marrow-derived dendritic cells", <i>International Immunology</i> , 13(6):713-721							
	2.	Batova, A. et al., (1999), "The Ch14.18-GM-CSF Fusion Protein Is Effective at Mediating Antibody-dependent Cellular Cytotoxicity and Complement-dependent Cytotoxicity <i>in Vitro</i> ", <i>Clinical Cancer Research</i> , 5:4259-4263.							
	3.	Frankel, A. et al., (1995), "IL2-Ricin Fusion Toxin Is Selectively Cytotoxic <i>in Vitro</i> to IL2 Receptor-Bearing Tumor Cells", <i>Bioconjugate Chem.</i> , 6:666-672.							
	4.	Gillies, S.D. et al., (1992), "Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells", <i>Proc. Natl. Acad. Sci. USA</i> , 89:1428-1432.							
	5.	Barker, E. et al., (1991), "Effect of a Chimeric Anti-Ganglioside GD <sub>2</sub> Antibody on Cell-mediated Lysis of Human Neuroblastoma Cells", <i>Cancer Research</i> , 51:144-149.							
	6.	Gillies, S.D. et al., (1991), "Expression of Genetically Engineered Immunoconjugates of Lymphotoxin and a Chimeric Anti-Ganglioside GD <sub>2</sub> Antibody" <i>Hybridoma</i> , 10(3):347-356.							
	7.	Deliyannis, G. et al., (2000), "A fusion DNA vaccine that targets antigen-presenting cells increases protection from viral challenge", <i>PNAS</i> , 97(12):6676-6680.							
EXAMINER Emily L.						DATE CONSIDERED 9/27/05			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.									
**Copies of references not provided at the time of this submission.									